Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.
A panel of federal advisers on Wednesday strongly supported the use of the Pfizer-BioNTech COVID-19 vaccine in teens ages 12 to 15.
The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) voted 14-0 on a question about whether to recommend use of the vaccine in this age group in the US population.
The US Food and Drug Administration (FDA) on May 10 issued an emergency use authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 in individuals 12-15 years old. FDA first cleared the Pfizer-BioNTech vaccine through an EUA in December for those ages 16 and older.
Now that ACIP has issued its recommendation it’s up to CDC Director Rochelle Walensky, MD, to give the final yea or nay for full federal clearance of the vaccine.
Vaccine “Safe and Effective”
Separately, the American Academy of Pediatrics (AAP) issued a statement on Wednesday in support of vaccinating all children ages 12 and older who are eligible for the federally authorized COVID-19 vaccine.
“As a pediatrician and a parent, I have looked forward to getting my own children and patients vaccinated, and I am thrilled that those ages 12 and older can now be protected,” said AAP President Lee Savio Beers, MD, in a statement. “The data continue to show that this vaccine is safe and effective. I urge all parents to call their pediatrician to learn more about how to get their children and teens vaccinated.”
The expanded clearance for the Pfizer vaccine is seen as a critical step for allowing teens to resume activities on which they missed out during the pandemic.
“We’ve seen the harm done to children’s mental and emotional health as they’ve missed out on so many experiences during the pandemic,” Beers said. “Vaccinating children will protect them and allow them to fully engage in all of the activities — school, sports, socializing with friends and family — that are so important to their health and development.”
Kerry Dooley Young is a freelance journalist based in Washington, DC. She is the core topic leader on patient safety issues for the Association of Health Care Journalists. Young earlier covered health policy and the federal budget for Congressional Quarterly/CQ Roll Call and the pharmaceutical industry and the Food and Drug Administration for Bloomberg. Follow her on Twitter at @kdooleyyoung.
Follow Medscape on Facebook, Twitter, Instagram, and YouTube.
Source: Read Full Article